MNM CONFERENCES Epigenetics Discovery Congress€¦ · explore the potential of epigenetics to...
6
M NM CONFERENCES M NM CONFERENCES 2nd Annual Epigenetics Discovery Congress 8 th - 9 th September 2016, London, UK M NM CONFERENCES Epigenetics has flourished to become one of the most revolutionary areas of science over the past decade. Also, advances in the understanding of epigenetic processes, have led to a burst in interest in this area as a potential source of new targets for the discovery of medicines. While the promise of epigenetics is significant, it also presents some interesting challenges like pathways and mechanisms underlying epigenetics, using right screening platforms, bottlenecks in translational and clinical phase, collating epigenetics data with proper analysis and finding the right biomarkers. At the 2 nd Annual Epigenetics Discovery Congress, which will be held on 8-9 September 2016 in London, UK aims to provide a platform for researchers, academics and industry professionals working in epigenetic research to avail an opportunity & explore the potential of epigenetics to contribute towards novel and existing therapeutics, current progress and trends in the inclusion of epigenetics in drug discovery and development. Along with the advancements in technologies and solutions, the conference will also focus on highlighting some of the emerging trends in terms of drug discovery with respect to evolving targets, inhibitors, biomarkers and clinical success of epigenetics across various diseases. Review the importance of the strongly growing epigenetic market Discuss the latest epigenetic breakthroughs in your field of epigenetic studies Explore new avenues to network and showcase your epigenetic research work and discoveries Discuss the use of Biomarkers as a tool for achieving optimal detection Network with your academic and industry colleagues to brainstorm on latest epigenetic application Review the latest epigenetic tools and technologies available in the market to aid your research Why Attend? Sponsor/Exhibitor:
Transcript of MNM CONFERENCES Epigenetics Discovery Congress€¦ · explore the potential of epigenetics to...
MNM CONFERENCES
FOR MORE INFORMATION PLEASE CONTACT
Ajay at [email protected] | +9120 67 046 816
MNM CONFERENCES
1FOR MORE INFORMATION PLEASE CONTACT
Ajay at [email protected] | +9120 67 046 816 1
2nd AnnualEpigenetics Discovery Congress 8th - 9th September 2016, London, UK
MNM CONFERENCES
Epigenetics has fl ourished to become one of the most revolutionary areas of science over the past decade. Also, advances in the understanding of epigenetic processes, have led to a burst in interest in this area as a potential source of new targets for the discovery of medicines.
While the promise of epigenetics is signifi cant, it also presents some interesting challenges like pathways and mechanisms underlying epigenetics, using right screening platforms, bottlenecks in translational and clinical phase, collating epigenetics data with proper analysis and fi nding the right biomarkers.
At the 2nd Annual Epigenetics Discovery Congress, which will be held on 8-9 September 2016 in London, UK aims to provide a platform for researchers, academics and industry professionals working in epigenetic research to avail an opportunity & explore the potential of epigenetics to contribute towards novel and existing therapeutics, current progress and trends in the inclusion of epigenetics in drug discovery and development.
Along with the advancements in technologies and solutions, the conference will also focus on highlighting some of the emerging trends in terms of drug discovery with respect to evolving targets, inhibitors, biomarkers and clinical success of epigenetics across various diseases.
Review the importance of the strongly growing epigenetic market
Discuss the latest epigenetic breakthroughs in your fi eld of epigenetic studies
Explore new avenues to network and showcase your epigenetic research work and discoveries
Discuss the use of Biomarkers as a tool for achieving optimal detection
Network with your academic and industry colleagues to brainstorm on latest epigenetic application
Review the latest epigenetic tools and technologies available in the market to aid your research
Why Attend?
Explore new avenues to network and showcase your epigenetic research work and discoveries
Network with your academic and industry colleagues to brainstorm on latest epigenetic application
Review the latest epigenetic tools and technologies available in the market to aid your research
Sponsor/Exhibitor:
MNM CONFERENCES
FOR MORE INFORMATION PLEASE CONTACT
Ajay at [email protected] | +9120 67 046 816
MNM CONFERENCES
2
Speakers:
Advisory Panel:
Dr. Tamara MaesChief Scientifi c Offi cer,Oryzon, Spain
Dr. Paola B. ArimondoResearch Director,CNRS EtaC, France
Dr. Hajji NabilLecturer in epigenetics and translational oncology, Imperial College London, UK
Prof. A. GanesanProfessor of Chemical Biology University of East Anglia,Norwich, UK
Dr. Brian LohseAssociate Professor, EpiDiscoverY, Faculty of Health and Medical Sciences, Department of Drug Design and Pharmacology, University of Copenhagen, Denmark
Prof. Guro Elisabeth LindGroup leader Epigenetics, Department of Molecular Oncology, Institute for cancer research, Oslo University Hospital, Norway
Dr. Manfred KoeglDirector Oncology ResearchBoehringer Ingelheim, Vienna, Austria
Dr. Tobias A. KnochGroup Leader Biophysical Genomics, Cell Biology & GeneticsErasmus MC, Rotterdam,The Netherlands
Dr. Gian Gaetano TartagliaGroup Leader, Gene Function & Evolution, Centre for Genomic Regulation (CRG), Barcelona, Spain
Prof. Irene Maeve Rea Emeritus Professor, School of Medicine, Dentistry and Biomedical Science,Ulster University, Ireland
Prof. Dr. F.J. (Frank) DekkerAssociate professor, Medicinal Chemistry, University of Groningen, Netherlands
Dr. Stephen J ShuttleworthChief Scientifi c Offi cer Karus Therapeutics Ltd, England
Prof. Dr. Gianluca SbardellaAssociate Professor of Medicinal Chemistry, Head of EpigeneticMedChemLabUniversità di Salerno, Italy
Dr. Richard ChesworthSenior Vice President Molecular DiscoveryEpizyme, USA
Prof. Richard MeehanProgramme Leader, Chromosomes and Gene Expression MRC Human Genetics Unit MRC IGMM, University of Edinburgh, UK
Prof. Rosalind M JohnDivision Leader for Pathophysiology and RepairCardiff School of Biosciences, UK
Prof. Dr. Reinhard StögerAssociate Professor in EpigeneticsUniversity of Nottingham, England
Dr. Moshe SzyfGlaxo Smith Kline and James McGill Professor, Department of Pharmacology and Therapeutics, McGill University Medical School, Canada
Prof. Dr. Manon van EngelandDept. of Pathology, GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center, Netherlands
Dr. Hajji NabilLecturer in epigenetics and translational oncologyImperial College London, UK
Dr. Paola B. ArimondoResearch DirectorCNRS EtaC, France
Dr. Tamara MaesChief Scientifi c Offi cer Oryzon, Spain
Dr. Daniel VittCSO4SC AG, Germany
MNM CONFERENCES
FOR MORE INFORMATION PLEASE CONTACT
Ajay at [email protected] | +9120 67 046 816
MNM CONFERENCES
3
Conference Day One, Thursday, 8th September 201608:00 Registration and Refreshments
08:50 MnM Conferences’ Welcome Address
08:55 Opening remarks by the Chair
Developmental Biology and Environment
09:00 Structural and regulatory factors of chromatin for developing novel therapeutic approaches for human diseases• Chromatin Biology and Mechanism• Chromatin marks: Histone modifi cations, DNA modifi cations and novel discoveries• Role of chromatin in human diseasesProf. Dr. Gianluca Sbardella, Associate Professor of Medicinal Chemistry, Head of EpigeneticMedChemLab, Università di Salerno, Italy
09:25 Epigenetic profi ling and environmental challenge• 5mC/5hmC profi ling tracks environmental exposure in model systems• Allows identifi cation of potential epigenetic predictors of end point pathologies• Studying the effects of environmental triggers on the epigenome will enable identifi cation of novel biomarkersProf. Richard Meehan, Programme Leader, Chromosomes and Gene Expression, MRC Human Genetics Unit MRC IGMM, University of Edinburgh, UK
09:50 Stability and fl ux of DNA methylation patterns• Genomic programs regulating energy balance evolved to be buffered or ‘canalised’ against genetic variation• Large genetic regulatory networks can acquire novel epigenetic states in response to environmental challenges• A new metric to quantify and compare epigenetic fl exibility and stability across loci, cell types, and developmental stagesProf. Dr. Reinhard Stöger, Associate Professor in Epigenetics, University of Nottingham, England
10:15 Presentation by NuGEN
10:45 Morning Refreshments | Networking | Poster presentation | One to One meetings
11:30 Environmental programming of maternal care and offspring behaviour by an epigenetic mechanism• Prenatal environment and the developing placental epigenome• Placental function and fetal growth• Dual programming of maternal care and offspring behaviour Prof. Rosalind M John, Division Leader for Pathophysiology and Repair, Cardiff School of Biosciences, UK
Translational Epigenetics11:55 Overcoming bottlenecks in the translational phase
This session will focus on overcoming bottlenecks in the translational phaseSpeaker TBA
12:20 Epigenetic regulation of the tumour micro environment (TME) - immuno oncology meets epigenetics• 4SC-202 is a new clinical stage epigenetic regulator of the TME • Enhanced T-cell infi ltration in tumours may offer a unique clinical boost of responses to checkpoint inhibitors • Further approaches of epigenetic immune regulation - beyond HDAC inhibitors Dr. Daniel Vitt, Vorstand, CSO, 4SC AG, Germany
12:45 Epigenetic regulation of epithelial homeostasis: an emerging story of health and disease• Urothelium is a transitional epithelium that functions as a self-repairing, urinary barrier within the bladder and associated urinary tract. • I will present experimental evidence that at the cellular level, the homeostasis of human urothelium is regulated epigenetically • I will further consider how local and environmental factors effecting epigenetic deregulation can create an imbalance in tissue
homeostasis, with chronic ulceration versus cancer at the extremes of chronic bladder diseaseProf. Jenny Southgate, Director, Jack Birch Unit, Department of Biology, University of York, England
MNM CONFERENCES
FOR MORE INFORMATION PLEASE CONTACT
Ajay at [email protected] | +9120 67 046 816
MNM CONFERENCES
4
13:10 Lunch | Networking | Poster presentation | One to One Meetings
14:10 Solution Provider Presentation; contact [email protected]
Clinical Epigenetics and Biomarkers
14:40 DNA methylation biomarkers for early and non-invasive detection and monitoring of bladder cancer • Using methylome sequencing (RRBS) to identify high performing DNA methylation biomarkers specifi c for bladder cancer• Leveraging biomarkers to reducing the mortality and economical costs of bladder cancerProf. Guro Elisabeth Lind, Group leader Epigenetics, Department of Molecular Oncology, Institute for cancer research, Oslo University hospital, Norway
15:05 Genetics or Lifestyle: Is Epigenetics the Missing link in the Longevity Phenotype? • Human longevity is a complex trait and increasingly we recognise that both genes and lifestyle interact in the longevity
phenotype.• Family clusters of nonagenarian and centenarian siblings, who show both exceptional age-span and health-span are likely to
have inherited facilitatory gene groups but also have nine decades of life experiences and behaviours which have interacted with their genetic profi les.
• Although much remains to be discovered, this lecture will discuss some of the epigenetic and environmental factors which appear important in good quality longevity and link known epigenetic mechanisms to themes identifi ed by nonagenarians themselves related to their longevity.
Prof. Irene Maeve Rea, Emeritus Professor School of Medicine, Dentistry and Biomedical Science, Ulster University, Ireland
15:30 Afternoon Refreshments | Poster Presentation | Networking | One to One Meetings
16:15 Solution Provider Presentation; contact [email protected]
16:45 DNA methylation markers for management of cancer: pitfalls and perspectives• Discovery of DNA methylation markers• Implementation of methylation markers into clinical practice• Pitfalls and perspectivesProf. Dr. Manon van Engeland, Dept. of Pathology, GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center, Netherlands
17:10 Decoding the 3D Multi-Loop Aggregate/Rosette Chromatin Architecture, Dynamics, and Functional Epigenetics of Genomes• Novel combination of chromosome interaction capture (T2C) and fl uorescence correlation spectroscopy (FCS)• Final architecture and dynamics of genome organization• The tight entanglement of sequence, structure, and functional epigenetics Dr. Tobias A. Knoch, Group Leader Biophysical Genomics, Cell Biology & Genetics, Erasmus MC, Rotterdam, The Netherlands
17:35 Closing Remarks by the Chair
17:45 Networking and Drinks Reception
Supporting Association:
THE EPIGENETICS SOCIETY
MNM CONFERENCES
FOR MORE INFORMATION PLEASE CONTACT
Ajay at [email protected] | +9120 67 046 816
MNM CONFERENCES
5
Conference Day Two, Friday, 9th September 201608:15 Registration and Refreshments
08:50 MnM Conferences’ Welcome Address
08:55 Opening remarks by the Chair
09:00 Keynote: Drug Discovery and HMTs• Overview of Histone Methyl transferases• Drug discovery of HMTs• Clinical Data of HMTs so farDr. Richard Chesworth, Senior Vice President Research, Epizyme, USA
Epigenetics Inhibitors and Emerging Targets
09:25 KATching lysine acetylations in infl ammation• Role of lysine acetylation in infl ammation• Development of histone acetyltransferase inhibitors• Selective HDAC inhibitors in infl ammationProf. Dr. Frank Dekker, Associate professor, Medicinal Chemistry, University of Groningen, Netherlands
09:50 Targeting DNA methylation in cancer cells with non-nucleoside inhibitors• We have designed novel non-nucleoside inhibitors of DNA methyltransferases able to demethylate and reactive tumor
suppressor genes. • We applied three chemical strategies: High-Throughput Screening of chemical libraries, rational drug design based on
molecular modeling and the pharmacomodulation of known inhibitors. • The cellular consequences of this DNA demethylation are studied in comparison to nucleoside inhibitor decitabine.Dr. Paola B. Arimondo, CNRS, ETaC, France
10:15 Panel discussion Fostering the culture of collaborations between industry and academic researchers to deliver innovation, translation and impact of epigenetics on a global scale
• Nurturing translational research• Initiating drug discovery projects in collaboration with industry• Improving clinical development-Dr. Stephen Shuttleworth, CSO, Karus Therapeutics, UK-Prof. A. Ganesan, Professor of Chemical Biology, University of East Anglia, Norwich, UK- Dr. Moshe Szyf, Glaxo Smith Kline and James McGill Professor, Department of harmacology and Therapeutics,McGill University Medical School, Canada
-Prof. Jenny Southgate, Director, Jack Birch Unit, Department of Biology, University of York, England
10:45 Morning Refreshments – Networking – Poster presentation and One to One meetings
11:30 Solution Provider Presentation; Please contact Steve Hambrook at [email protected]
12:00 Strategies to identify new inhibitor scaffolds for Histone Demethylases and Methylases• Strategies to discover new scaffolds: small molecules and peptides• DNA encoded peptide libraries• Fluorescence Assay development and testing on epigenetic targetsDr. Brian Lohse, Associate Professor, EpiDiscoverY, Faculty of Health and Medical Sciences, Department of Drug Design and Pharmacology, University of Copenhagen, Denmark
12:25 Is two better than one? Multitarget epigenetic inhibitors• Dual HDAC plus kinase inhibitors• Dual HDAC inhibitor plus receptor ligand• Dual epigenetic targetingProf. A. Ganesan, Professor of Chemical Biology, University of East Anglia, Norwich, UK
MNM CONFERENCES
FOR MORE INFORMATION PLEASE CONTACT
Ajay at [email protected] | +9120 67 046 816
MNM CONFERENCES
6
12:50 Probing genome readers: the generation of an in vivo active bromodomain inhibitor for BRD9• The BAF complex is a potential target in cancer therapy• Structure based drug design of a selective inhibitor of BRD9• On-target chemical inhibition of Brd9 limits the proliferation of acute myeloid leukemia cellsDr. Manfred Koegl, Director Oncology Research, Boehringer Ingelheim, Vienna, Austria
13:15 Lunch – Networking – Poster presentation and One to One Meetings
14:15 Presentation by Diagenode
Cancer and Neurodevelopment
14:45 Targeting DNA methylation in neuropsychiatric disease; instructions from cancer epigenetics • DNA methylation mediating the impact of early exposures on behavioral phenotypes• Strategies of epigenetic therapeutics in cancer guiding approaches to neuropsychiatry• Epigenetic strategies towards treatment of behavioral disorders: addiction as a modelDr. Moshe Szyf, Glaxo Smith Kline and James McGill Professor, Department of harmacology and Therapeutics,McGill University Medical School, Canada
15:10 Development of LSD1 inhibitors for the treatment of oncological and neurodegenerative disease• Development of ORY-1001 and ORY-2001• Identifi cation of the drugs’ modes of action• Status of ongoing clinical researchDr. Tamara Maes, Chief Scientifi c Offi cer, Oryzon, Spain
15:35 Design and Development of a Novel HDAC6-Selective Inhibitor, KA2507, for Hematological Cancer Treatment and Solid Tumor Immunotherapy
• Functional mechanisms of lncRNAs• Application of high-throughput technologies, to clarify how lncRNAs regulate diverse biological processes in physiological and
pathophysiological statesDr. Stephen Shuttleworth, CSO, Karus Therapeutics, UK
16:00 Afternoon Refreshments | Poster Presentation | Networking
Bioinformatics Development in Epigenetics
16:40 A computational approach for identifi cation of protein-RNA interactions uncovers direct binders of Xist lncRNA• Global Score algorithm to calculate interactions of proteins and lncRNAs at nucleotide and amino acid resolution• Investigating protein binding to the Xist lncRNA, which orchestrates X Chromosome inactivation• Validating calculations by means of enhanced individual nucleotide CLIP method (eCLIP)• Testing method against a number of nucleotide-binding proteinsDr. Gian Gaetano Tartaglia, Group Leader, gene Function & Evolution, Centre for Genomic Regulation (CRG), Barcelona, Spain
17:05 Role of bioinformatics in overcoming the challenges of collating epigenetics data together• Identifying novel tools and methods to anaylse epigenetics data for experimental validation• How can bioinformatics facilitate epigenetics researches?• Recent advancements in bioinformatics for epigenetics drug discoverySpeaker: TBA
17:30 Closing Remarks by the Chair
Media Partner
